Report ID: SQMIG35A2527
Monoclonal Antibody Therapy Market Size, Share, Growth Analysis, By Type(Murine Antibodies, Chimeric Antibodies, Humanised Antibodies and Fully Human Antibodies), By Application(Oncology, Autoimmune Diseases, Infectious Diseases, Inflammatory Conditions and Others.), By Region - Industry Forecast 2025-2032
Report ID:
SQMIG35A2527 |
Region:
Global |
Published Date: February, 2024
Pages:
157
|
Tables:
64 |
Figures:
75
Monoclonal Antibody Therapy Market News
- In June 2023, Bristol-Myers Squibb Company announced the approval of its new monoclonal antibody therapy, Brexucabtagene autoleucel (JCAR015), for the treatment of adult patients with relapsed or refractory multiple myeloma who have received at least four prior therapies. Brexucabtagene autoleucel is a type of CAR T-cell therapy, which is a type of immunotherapy that uses a patient's own immune cells to fight cancer. In Brexucabtagene autoleucel, a patient's white blood cells are removed from their body, genetically modified to express a chimeric antigen receptor (CAR), and then infused back into the patient. The CAR helps the white blood cells to recognize and kill cancer cells.
- In May 2023, Eli Lilly and Company announced the approval of its new monoclonal antibody therapy, Taltz (ixekizumab), for the treatment of adults with moderate to severe plaque psoriasis. Taltz is a human monoclonal antibody that works by blocking the activity of a protein called interleukin-17A (IL-17A). IL-17A is involved in the inflammatory response that causes psoriasis, and by blocking its activity, Taltz helps to reduce inflammation and improve skin lesions.
- In April 2023, Genentech (Roche) announced the approval of its new monoclonal antibody therapy, Ocrevus (ocrelizumab), for the treatment of adults with relapsing multiple sclerosis. Ocrevus is a human monoclonal antibody that works by targeting B cells, a type of white blood cell that plays a role in the immune system. By targeting B cells, Ocrevus helps to reduce inflammation and slow the progression of multiple sclerosis.
- In March 2023, Johnson & Johnson announced the approval of its new monoclonal antibody therapy, Tremfya (guselkumab), for the treatment of adults with moderate to severe plaque psoriasis. Tremfya is a human monoclonal antibody that works by blocking the activity of a protein called interleukin-23 (IL-23). IL-23 is involved in the inflammatory response that causes psoriasis, and by blocking its activity, Tremfya helps to reduce inflammation and improve skin lesions.
- In February 2023, Novartis AG announced the approval of its new monoclonal antibody therapy, Kymriah (tisagenlecleucel), for the treatment of children and young adults with B-cell acute lymphoblastic leukaemia (ALL) that is refractory or has relapsed after two or more prior therapies. Kymriah is a type of CAR T-cell therapy, which is a type of immunotherapy that uses a patient's own immune cells to fight cancer. In Kymriah, a patient's white blood cells are removed from their body, genetically modified to express a chimeric antigen receptor (CAR), and then infused back into the patient. The CAR helps the white blood cells to recognize and kill cancer cells.
Monoclonal Antibody Therapy Market Report Snapshots
Want to customize this report?
Our industry expert will work with you to provide you with customized data in a short amount of time.
REQUEST FREE CUSTOMIZATION
USA (+1) 351-333-4748
